» Articles » PMID: 16923742

Expression of Platelet Collagen Receptor Glycoprotein VI is Associated with Acute Coronary Syndrome

Overview
Journal Eur Heart J
Date 2006 Aug 23
PMID 16923742
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Platelet collagen receptor glycoprotein VI (GPVI) is critical for the formation of arterial thrombosis. In this observational study, we examined the platelet surface expression of GPVI in patients with symptomatic coronary artery disease (CAD).

Methods And Results: We evaluated a consecutive cohort of 367 patients with symptomatic CAD, who underwent coronary angiography. The surface expression of platelet activation markers (GPVI, CD62P, and CD42b) was determined by flow cytometry. Patients with acute coronary syndrome (ACS) showed a significantly enhanced GPVI expression on admission when compared with patients with stable angina pectoris (SAP) (ACS: 21.4+/-9.7; SAP: 18.6+/-7.1 mean fluorescence intensity+/-SD; P=0.004). The expression of GPVI correlated with CD62P (r=0.702; P=0.001). Logistic regression analysis demonstrated that on admission, elevated platelet GPVI expression was associated with ACS, independent of markers of myocardial necrosis such as troponin and creatine kinase.

Conclusion: Platelet GPVI surface expression is elevated in patients with ACS and is associated with imminent acute coronary events. The determination of the platelet-specific thrombotic marker GPVI may help to identify patients at risk before myocardial ischaemia is evident.

Citing Articles

The humanized platelet glycoprotein VI Fab inhibitor EMA601 protects from arterial thrombosis and ischaemic stroke in mice.

Navarro S, Talucci I, Gob V, Hartmann S, Beck S, Orth V Eur Heart J. 2024; 45(43):4582-4597.

PMID: 39150906 PMC: 11560278. DOI: 10.1093/eurheartj/ehae482.


Evaluation of the effect of eltrombopag therapy on the platelet collagen receptor glycoprotein VI (GPVI) expression and soluble GPVI levels in young patients with immune thrombocytopenia.

Tantawy A, Elsherif N, Ebeid F, El-Gamal R, Rahman Ismail E, Kenny M J Thromb Thrombolysis. 2022; 55(2):243-251.

PMID: 36479670 PMC: 10011314. DOI: 10.1007/s11239-022-02734-1.


Platelet Subtypes in Inflammatory Settings.

Hamad M, Krauel K, Schanze N, Gauchel N, Stachon P, Nuehrenberg T Front Cardiovasc Med. 2022; 9:823549.

PMID: 35463762 PMC: 9021412. DOI: 10.3389/fcvm.2022.823549.


ADP-Mediated Upregulation of Expression of CD62P on Human Platelets Is Critically Dependent on Co-Activation of P2Y1 and P2Y12 Receptors.

Anderson R, Theron A, Steel H, Nel J, Tintinger G Pharmaceuticals (Basel). 2020; 13(12).

PMID: 33255391 PMC: 7760858. DOI: 10.3390/ph13120420.


Molecular Drivers of Platelet Activation: Unraveling Novel Targets for Anti-Thrombotic and Anti-Thrombo-Inflammatory Therapy.

Chatterjee M, Ehrenberg A, Toska L, Metz L, Klier M, Krueger I Int J Mol Sci. 2020; 21(21).

PMID: 33114406 PMC: 7662962. DOI: 10.3390/ijms21217906.